Treatment Emergent Dolutegravir Resistance Mutations in Individuals Naive to HIV-1 Integrase Inhibitors: A Rapid Scoping Review.

ABSTRACT: Background: Dolutegravir (DTG)-based antiretroviral therapy (ART) rarely leads to virological failure (VF) and drug resistance in integrase strand transfer inhibitor (INSTI)-naïve persons living with HIV (PLWH). As a result, limited data are available on INSTI-associated drug resistance mutations (DRMs) selected by DTG-containing ART regimens. Methods: We reviewed studies published through July 2023 to identify those reporting emergent major INSTI-associated DRMs in INSTI-naïve PLWH receiving DTG and those containing in vitro DTG susceptibility results using a standardized assay. Results: We identified 36 publications reporting 99 PLWH in whom major nonpolymorphic INSTI-associated DRMs developed on a DTG-containing regimen and 21 publications containing 269 in vitro DT

SUBMITTER: Tao K 

PROVIDER: S-EPMC10536831 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature